Secondary Medical Use Part I: Analyzing the Consequences of Warner Lambert v. Generics (UK) Latest Updates

October 16, 2018 1:30pm

Corinna Sundermann
Senior Vice President IP Management
Fresenius Kabi Deutschland GmbH

Guido Pontremoli
Corporate IP Patent Director
Chiesi Farmaceutici

Nicolas Ruiz
Head of IP
Esteve

Dr Dieter Tzschoppe
Director,Healthcare,
Biotechnology and
Chemistry
European Patent Office

  • Examining the decision of Warner-Lambert vs. Generics (UK) and the consequent impact this has had on secondary medical use patents
  • Discovering whether research with off-patent products to explore secondary medical use is commercially viable?
  • Understanding whether the decision will have a profound impact on nation prescribing software?
  • How will this impact generic companies?
  • Best practices for applying for and obtaining secondary medical use patents